Business Standard

Niche players bet on bringing in therapies to India from abroad

Sundyota Numandis is bringing in global formulations in probiotics, nutraceuticals, hytopharmaceuticals through licensing route

graph
Premium

graph

Sohini Das Ahmedabad
Health care and pharma firms in niche therapies have sensed gains in bringing in drugs to India through deals with foreign companies and launching them under their brands.

Ahmedabad-based Sundyota Numandis Group has taken the licensing route to bring in products in probiotics, pharmabiotics, nutraceuticals, and phytopharmaceuticals (sourced from botanical extracts) from international firms.

Sundyota has also tied up with leading pharma players here such as Abbott India, Zydus Cadila, Alkem, Cipla, USV Pharma, Mankind Pharma, Ajanta Pharma, and Eris Lifesciences for manufacturing products that these players can launch under their brands.

Banking on these tie-ups, the firm is expecting to touch a

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Feb 26 2018 | 5:44 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com